Article info
PDFBasic and translational research
Extended report
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
- Correspondence to Professor Gabriela Riemekasten, Department of Rheumatology, University Hospital Schleswig-Holstein—Campus Lübeck, Ratzeburger Allee 160, Lübeck 23538, Germany; Gabriela.Riemekasten{at}uksh.de
Citation
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
Publication history
- Received April 13, 2015
- Revised July 30, 2015
- Accepted August 12, 2015
- First published August 31, 2015.
Online issue publication
April 20, 2023
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/